EP.07D.05 Molecular Testing Care Gap Analysis of EGFR Mutation for Early-Stage NSCLC Patients in Community Practices
J. Dow(Tempus Labs (United States)), J. Patel(Northwestern University), Sandra Monzón(Tempus Labs (United States)), Iker Huerga(Tempus Labs (United States)), Halla Nimeiri(Tempus Labs (United States)), Candice R. Gurbatri(Tempus Labs (United States)), N. Zimmerman(Tempus Labs (United States)), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Weidong Zhao(University of Science and Technology of China), V. Erese(Tempus Labs (United States)), Ezra E.W. Cohen(Moores Cancer Center), C. ScottoDiVetta(Tempus Labs (United States)), Ann Barrett(Tempus Labs (United States))
Cited by 0
Related Papers
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|746
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
|Science Translational Medicine|2020|600